Recently Listed Tvardi Therapeutics’ Lead Drug ‘Positioned To Drive Broad Improvement’, Analyst Sees Over 150% Stock Upside

All NewsJune 13, 2025

Tvardi advances fibrosis drug TTI-101 in IPF and liver cancer as Piper initiates with $78 target; merger boosts cash runway into late 2026.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent